TCG Crossover, a Palo Alto, CA- and NYC-based life sciences-focused investment firm with a flexible mandate to invest in both private and public companies, closed its second fund, TCGX Fund II, with $1B in capital.
The fund received support from new and existing limited partners with commitments coming globally from investors in North America, Europe, the Middle East, and Asia.
Founded in 2021 by Dr. Chen Yu, a former Managing Partner at Vivo Capital, TCGX invests exclusively in innovative drug discovery companies seeking to make an impact on patients.
The firm has raised more than $1.8B in total capital. TCGX Fund I, the inaugural fund launched in February 2021, delivered a differentiated track record of M&A and IPOs.
Dr. Yu has over 20 years of experience investing in both public and privately held life sciences companies globally. As part of the initiation of Fund II, TCGX announced the promotion of Cariad Chester to Managing Partner and Giuliano Marostica to Partner.
Within the last 18 months, the firm has also added a number of other members to the team:
- Ed Amorosi, Head of Capital Formation & Investor Relations
- Susan Wang, Associate
- Haithem Laaribi, Associate
- George Feng, Analyst